Suppr超能文献

米多君治疗血液透析低血压患者

Midodrine treatment for patients with hemodialysis hypotension.

作者信息

Flynn J J, Mitchell M C, Caruso F S, McElligott M A

机构信息

Department of Medicine, Monmouth Medical Center, Long Branch, New Jersey, USA.

出版信息

Clin Nephrol. 1996 Apr;45(4):261-7.

PMID:8861803
Abstract

Hypotension is the principal complication of chronic hemodialysis. Autonomic insufficiency is thought to be a primary contributing cause of hemodialysis hypotension. We treated patients who experience hemodialysis hypotension with midodrine, a selective alpha-1 adrenergic pressor agent in an initial effort to assess potential efficacy. Twenty-one patients who experienced severe hypotension during hemodialysis participated in this study. To qualify, patients had to exhibit a fall of > or = 30 mmHg in systolic blood pressure with associated clinical symptoms during hemodialysis. The lowest intra- and post-dialysis blood pressures were monitored for five consecutive hemodialysis treatment periods before receiving midodrine, as a baseline. After the patients were titrated to a maintenance midodrine dose, the lowest intra- and post-dialysis blood pressure data were again collected for five consecutive dialysis treatments. Hemodialysis blood pressures on midodrine treatment were compared to baseline to evaluate the effect of midodrine. Midodrine given at a mean treatment dose of 8 mg (range 2.5-25) significantly increased the mean (+ or - SE) minimal systolic pressure from 93.1 "+ or - " 3.8 to 107.1 + or - 3.2 mmHg (p <0.01) and elevated the mean diastolic pressure from 52.3 + or - 2.9 to 57.9 + or - 2.3 mmHg during hemodialysis. Also, the post-dialysis blood pressures (systolic/diastolic) were significantly increased from 115.6 + or - 3.1/62.3 + or - 2.1 to 129.9 + or - 3.9/68.1 + or - 1.7 mmHg (p <0.01 and 0.05, respectively). No apparent clinical or laboratory abnormalities were observed. Oral midodrine appears to be a safe and effective therapy for the treatment of hemodialysis hypotension.

摘要

低血压是慢性血液透析的主要并发症。自主神经功能不全被认为是血液透析低血压的主要促成原因。我们用米多君(一种选择性α-1肾上腺素能升压药)治疗经历血液透析低血压的患者,作为初步评估其潜在疗效的尝试。21名在血液透析期间经历严重低血压的患者参与了本研究。为符合条件,患者在血液透析期间收缩压必须下降≥30 mmHg并伴有相关临床症状。在接受米多君治疗前,连续五个血液透析治疗周期监测透析期间及透析后的最低血压,作为基线。在患者滴定至米多君维持剂量后,再次连续收集五个透析治疗的透析期间及透析后最低血压数据。将米多君治疗时的血液透析血压与基线进行比较,以评估米多君的效果。平均治疗剂量为8 mg(范围2.5 - 25 mg)的米多君显著提高了平均(±标准误)最低收缩压,从93.1±3.8 mmHg升至107.1±3.2 mmHg(p<0.01),并在血液透析期间将平均舒张压从52.3±2.9 mmHg提高至57.9±2.3 mmHg。此外,透析后血压(收缩压/舒张压)从115.6±3.1/62.3±2.1 mmHg显著升至129.9±3.9/68.1±1.7 mmHg(分别为p<0.01和0.05)。未观察到明显的临床或实验室异常。口服米多君似乎是治疗血液透析低血压的一种安全有效的疗法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验